New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
11:14 EDTTSRX, FSL, ZIOP, IRBT, EGLEHigh option volume stocks: TSRX FSL ZIOP IRBT EGLE
News For TSRX;FSL;ZIOP;IRBT;EGLE From The Last 14 Days
Check below for free stories on TSRX;FSL;ZIOP;IRBT;EGLE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:39 EDTZIOPZiopharm, Solasia enter global license, collaboration agreement for darinaparsin
Subscribe for More Information
July 30, 2014
11:22 EDTFSLOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTFSLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:35 EDTFSLFreescale upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
July 24, 2014
16:25 EDTFSLFreescale sees Q3 sales $1.19B-$1.23B, consensus $1.2B
Subscribe for More Information
16:24 EDTFSLFreescale reports Q2 adjusted EPS 38c, consensus 37c
Subscribe for More Information
10:26 EDTIRBTOptions with decreasing implied volatility
Subscribe for More Information
July 23, 2014
14:14 EDTFSLFollow-up: Freescale downgraded at Needham
As previously reported, Needham downgraded Freescale to Hold from Strong Buy. The firm downgraded shares citing the China 4G LTE inventory correction. overall softness in networking, and risk of lowered guidance.
14:06 EDTFSLFreescale downgraded to Hold from Buy at Needham
11:21 EDTIRBTOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
July 22, 2014
16:05 EDTIRBTiRobot sees FY14 EPS $1.10-$1.20 vs. previous $1.00-$1.15
Subscribe for More Information
16:04 EDTIRBTiRobot sees Q3 EPS 32c-35c, consensus 36c
Sees Q3 revenue $133M-$136M, consensus $149.5M.
16:04 EDTIRBTiRobot reports Q2 EPS 28c, consensus 22c
Subscribe for More Information
13:13 EDTIRBTiRobot technical remarks ahead of results
Subscribe for More Information
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use